Precommitment is a choice to restrict one’s future freedom. This strategy is used to address “weakness of will,” when people fear that their later choices will be damaging to their overall well-being. Through precommitment, people can authorize constraints on their freedom to make such choices.
In the past, precommitment has been endorsed as a strategy to treat addiction and mental health problems. Proponents have argued that individuals facing these problems should be authorized to make legally enforceable agreements consenting to treatment and hospitalization that is later unwanted. Yet legal and ethical concerns have presented barriers to implementing such agreements.
Precommitment is in the spotlight again, this time as a potential treatment strategy for people battling opioid use disorder. Implanted devices can automatically deliver anti-addiction drugs for several months, with the goal of reducing the impulsive behavior that leads to relapse in many individuals reliant on daily pills or monthly injections to counter their addiction. Accepting an implant is a form of precommitment to long-term use of medication-assisted therapy.
Precommitment is a choice to restrict one's future freedom. This strategy is used to address “weakness of will,” when people fear that their later choices will be damaging to their overall well-being.Footnote 1 Through precommitment, people can authorize constraints on their freedom to make such choices.Footnote 2
In the past, precommitment has been endorsed as a strategy to treat addiction and mental health problems. Proponents have argued that individuals facing these problems should be authorized to make legally enforceable agreements consenting to treatment and hospitalization that is later unwanted.Footnote 3 Yet legal and ethical concerns have presented barriers to implementing such agreements.
Precommitment is in the spotlight again, this time as a potential treatment strategy for people battling opioid use disorder. Implanted devices can automatically deliver anti-addiction drugs for several months, with the goal of reducing the impulsive behavior that leads to relapse in many individuals reliant on daily pills or monthly injections to counter their addiction.Footnote 4 Accepting an implant is a form of precommitment to long-term use of medication-assisted therapy.
Naltrexone is one of three major drugs used to treat opioid use disorder.Footnote 5 In 2019, Columbia University announced that the National Institute on Drug Abuse had agreed to fund research evaluating the safety and effectiveness of a long-acting naltrexone implant called the OLANI.Footnote 6 The goal is to determine whether the implants allow more people to achieve long-term sobriety. Although some evidence has been collected on the implant's risks and benefits, authorities in most countries say that more rigorous evaluation is needed to justify its approval for widespread clinical use.Footnote 7
Long-acting naltrexone implants raise some of the same concerns that precommitment agreements raise. Successful use of the implants will require attention to three central issues. First, what constitutes informed and voluntary consent to this form of treatment? What should individuals understand before consenting to receive an implant that could later be unwanted? Second, does a recipient's previous consent supply adequate justification for clinicians and researchers to refuse that person's later request for implant removal? Third, what standard of competency should apply when individuals with naltrexone implants seek to override their previous decisions? Can the cravings associated with addiction compromise a person's competency to withdraw an earlier consent to implantation?
This article analyzes these issues. In Part I, I describe existing treatment options for people with opioid use disorder, as well as the potential benefits and harms of long-acting naltrexone implants. Part II examines precommitment strategies in the context of health decisions. In this part, I consider existing law relevant to the use of precommitment strategies. I also review ethical arguments for and against the use of such strategies in addiction as well as general mental health treatment.Footnote 8 I conclude with recommendations for researchers, clinicians, policy officials, and opioid users making decisions about naltrexone implants.Footnote 9
I. MEDICATION-ASSISTED THERAPY FOR OPIATE USE DISORDER
Opioid use disorder is a major public health problem, linked to high rates of mortality and morbidity in the U.S. population. Hundreds of thousands of people are now addicted to opioids, and the demand for effective treatment is greater than ever.Footnote 10
Three drugs are currently used to treat people with opioid use disorder.Footnote 11 The drugs function in different ways. Methadone and buprenorphine are themselves opioids, but are designed to relieve pain while lowering the risks associated with prescription opioid painkillers as well as prohibited opioids like heroin.Footnote 12 Naltrexone is an opioid antagonist, which means it blocks the brain's opiate receptors. By removing the pain-relieving and other positive effects of opioids, naltrexone can reduce the likelihood that individuals will persist in opioid use.Footnote 13
Methadone and buprenorphine have been demonstrated to be effective in preventing relapse among people with substance use disorder.Footnote 14 Although people require ongoing treatment to address their cravings and compulsions, they are able to avoid the negative health and social consequences of addiction.Footnote 15 Both methadone and buprenorphine are susceptible to misuse, however, including diversion to others seeking the relief the medications can provide. Some people also continue to use other opioids while taking methadone or buprenorphine, which exposes them to the risk of overdose.Footnote 16
Naltrexone has both advantages and disadvantages in comparison with methadone and buprenorphine. Naltrexone is attractive to people whose overriding goal is to eliminate their drug dependence.Footnote 17 Naltrexone's biggest disadvantage is that people must undergo complete detoxification before beginning the medication, a process that is so physically and psychologically difficult that many cannot complete it.Footnote 18 Some opioid users also say that naltrexone is less effective than methadone and buprenorphine in reducing their cravings for opioids.Footnote 19 Experts warn that naltrexone alone is not a panacea for opioid addiction.Footnote 20 Simply removing the pleasant effects of opioids is often not enough to counter what is a “complex syndrome involving a number of genetic, physiological, neurobiological, and psychological factors.”Footnote 21
Treatment involving daily naltrexone pills puts extreme demands on people with opioid use disorder. Every day they must resist the temptation to once more experience the pleasurable effects that opioids deliver. The difficulty of maintaining this resistance is a major contributor to high relapse rates among people taking naltrexone on a daily basis.Footnote 22
In an effort to improve naltrexone's effectiveness, researchers have developed methods to reduce the temptation to stop treatment. One such method, a long-acting injection, was approved by the U.S. Food and Drug Administration (FDA) in 2010.Footnote 23 Studies have shown that the injection, which patients receive monthly, significantly increases their ability to remain in treatment.Footnote 24
Naltrexone implants are designed to improve on these results. Implants deliver naltrexone over a period of months, further reducing patients' opportunities to stop the medication. Patients often need to receive anti-addiction medication for at least six months to avoid relapse.Footnote 25 Different versions of the implant have been developed, although the OLANI device is the only one designed to last for at least six months.Footnote 26 The hope is that this device will enable recipients to maintain opioid abstinence for a longer time than they could with other forms of naltrexone treatment.Footnote 27
Although experts agree that more testing is needed, some research has been conducted on long-acting naltrexone implants.Footnote 28 The existing data on patient benefit are promising. Yet the data also point to concerns that must be addressed before the device becomes widely available. Some of the concerns are related to the harm that can come when people change their minds about wanting the device.Footnote 29
Australian authorities have not approved the OLANI for general clinical use, but a special program permits physicians to prescribe it “to patients at an increased risk of morbidity or mortality.”Footnote 30 Investigators in Australia have conducted research on the device, finding the implant superior to daily naltrexone pills in reducing opioid relapse in the post-treatment period.Footnote 31 Another study of the OLANI implant conducted in Norway compared it with the usual care provided to people who had undergone opioid detoxification.Footnote 32 Investigators in this study also reported benefit in the form of reduced opioid use following treatment.Footnote 33
Yet researchers have also reported risks associated with the OLANI implant. One study found that implant recipients had higher rates of overdose from non-opioid drugs such as amphetamines.Footnote 34 Recipients in search of the positive effects they previously experienced from opioids apparently sought those effects from other kinds of drugs. Some implants also had to be removed due to infection and patient dissatisfaction.Footnote 35
Two other noteworthy implant studies were conducted in Russia, where naltrexone is the only anti-addiction medication that is legally available.Footnote 36 The Russian studies evaluated an implant that delivers naltrexone for two to three months. A randomized controlled trial comparing the implant to daily pills and placebos found the implant significantly more effective in preventing relapse.Footnote 37 A second study evaluated treatment outcomes in people with both HIV and opioid addiction. Study participants receiving naltrexone implants had better HIV and anti-addiction treatment outcomes than those receiving daily naltrexone pills.Footnote 38
At the same time, both of the Russia-based studies documented risks associated with participants' desire to counter the implant's effects. Some implant recipients tried to remove the implants themselves.Footnote 39 According to researchers, there was a “higher proportion of patients with surgical infections with naltrexone implants compared with placebo implants, which researchers believe might be a result of addicts trying to take the implant out, possibly so they could get the full effect of an opiate hit again.”Footnote 40 In addition, one participant “tried to overcome [the implant] by taking vast quantities of heroin to get a high until he finally overdosed, barely surviving.”Footnote 41 Others have reported similar problems related to implant use.Footnote 42
In sum, the available information on naltrexone implants shows that some implant recipients are likely to regret their initial consent to the intervention, and that they could resort to drastic measures to negate that earlier choice. Investigators conducting the U.S. OLANI study should consider these possibilities in planning their research. Moreover, authorities deciding whether to approve long-acting naltrexone implants for clinical use should acknowledge and respond to the likelihood that some recipients will change their minds about the implants. In the next part, I examine the legal and ethical considerations that should shape their response.
II. LEGAL AND ETHICAL CONSIDERATIONS
A. Relevant Law
Three bodies of law are relevant to the use of long-acting naltrexone implants. First, the U.S. regulations governing research involving human subjects apply to federally funded studies on implants like the OLANI.Footnote 43 Second, if the FDA at some point approves the device, rules governing decision making about medical interventions will apply to its use. Third, advance directive laws, particularly those governing future-oriented decisions about mental health treatment, are also relevant to the use of long-acting naltrexone implants.Footnote 44
1. Implants in the Research Context
Federal research regulations require investigators to secure a person's voluntary and informed consent to study participation.Footnote 45 Before enrolling an individual in research, investigators must give that individual the facts that a reasonable person would want to know about the study.Footnote 46 This includes “any reasonably foreseeable risks and discomforts to the subject.”Footnote 47 Thus, potential study participants must be warned that they might later regret their decision to try the naltrexone implant.
The regulations also require investigators to tell prospective research subjects that “participation is voluntary … and the subject may discontinue participation at any time without penalty ….”Footnote 48 Furthermore, the regulations prohibit “exculpatory language through which the subject … is made to waive or appear to waive any of the subject's legal rights.”Footnote 49 This provision rules out the possibility of binding precommitment in naltrexone implant research, for it invalidates a participant's waiver of the right to withdraw from study participation.Footnote 50
Decisional capacity is required for participants to enter and withdraw from a study. The regulations fail to define decisional capacity, but authorities generally agree that the standard requires people to have the capacity to understand important information about the study.Footnote 51 The standard also requires people to have the capacity to appreciate how they could be affected by participation, including the personal impact of any harm the study could impose on them.Footnote 52
The regulations do allow studies to include participants lacking decisional capacity in certain circumstances. A “legally authorized representative” is an individual authorized under state law or institutional policy to make health care decisions on behalf of an incapable person.Footnote 53 Such representatives are empowered to consent to or refuse study participation, as well as to withdraw the incapable person from ongoing participation. In acting on behalf of the incapable person, representatives are expected to make choices that reflect the values and interests of that person. They are also expected to involve the person in decision making as much as possible, including obtaining the person's assent to the representative's choices.Footnote 54
2. Implants in the Medical Context
If research on long-acting naltrexone implants produces good results, the FDA could approve them for general patient use. State law governs individual decisions about health care, including decisions involving FDA-approved medical devices.Footnote 55 The basic rules governing medical treatment are roughly the same as the research rules in requiring a patient's informed and voluntary consent to treatment. Patients also have legal rights to withdraw their consent to treatment.Footnote 56 The law permits surrogates, generally family members, to make decisions on behalf of patients lacking decisional capacity. Surrogates are directed to make decisions based on the patient's former values and preferences, as well as the patient's best interests.Footnote 57
In contrast to the federal research regulations, the law governing medical treatment decisions recognizes a form of precommitment. Advance directive statutes authorize people to issue instructions about the treatment they would prefer if they later lose the ability to choose.Footnote 58 Individuals may also designate another person as their preferred decision maker in the event of incapacity.Footnote 59
Advance directive laws usually permit people to revoke their previous choices at any time, however, even if they have lost decision-making capacity.Footnote 60 But there are exceptions to this approach. A number of states have enacted statutes specifically recognizing mental health care advance directives, and some of these statutes restrict the individual's power to revoke the choices set forth in a directive.Footnote 61 In these jurisdictions, people lacking decisional capacity lack authority to revoke their previous choices.Footnote 62
Virginia's statute illustrates this approach. When a patient loses decision-making capacity, the Virginia law permits the patient's previously selected agent to make a treatment choice over the patient's objection. The patient's advance directive must explicitly authorize the agent to “make the health care decision at issue, even over the patient's later protest.”Footnote 63 The directive must include a licensed health professional's signed statement confirming that at the time the directive was created, the patient “was capable of making an informed decision” and understood the consequences of permitting future treatment under protest.Footnote 64
The Virginia law defines decisional incapacity as the inability to “understand the nature, extent or probable consequences of the proposed health care decision, or to make a rational evaluation of the risks and benefits of alternatives to that decision.”Footnote 65 The law directs patients' agents to take into account the risks and benefits of available treatment alternatives and to base “decisions on the beliefs, values, and preferences of the patient, or if they are unknown, on the patient's best interests.”Footnote 66
People with opioid use disorder are apparently eligible to make directives under this law, for it covers people whose decisional incapacity is produced by “mental illness, intellectual disability, or any other mental or physical disorder that precludes communication or impairs judgment.”Footnote 67 Thus, if the FDA eventually approves the OLANI or another long-acting naltrexone implant, states with laws like Virginia's could permit people to engage in a limited form of precommitment to ongoing treatment with the device. Below I discuss whether advance directive laws should permit this or any other form of precommitment to long-term naltrexone treatment.
B. The Ethics of Precommitment in Mental Health Treatment
Ethicists have debated mental health applications of precommitment for many years. A few writers have considered precommitment in the context of addiction, but most of the debate concerns precommitment in the context of psychiatric disorders.Footnote 68 The basic disagreement is over whether the preferences of a person at one point in time should prevail over the person's conflicting preferences at another time.
1. Precommitment in Addiction Treatment
Philosophers defending precommitment for people with addiction disorders emphasize the psychological and physical pressures that reduce the individual's ability to exercise autonomy. According to Chrisoula Andreou, one such philosopher, people with addiction disorders are often preoccupied with preventing the self-destructive behavior that relapse typically triggers.Footnote 69 Their “stable” or “considered” preferences are to refrain from such behavior, but their cravings produce a form of incapacity that prevents them from doing so. Andreou contends that in this incapacitated state, they continue to have a preference to refrain from self-destructive actions, but are temporarily unable to act accordingly.Footnote 70 According to Andreou, their ongoing preferences supply ethical justification for overriding their immediate desires to resume their addictive behavior.Footnote 71 Thus, when people battling addiction enlist another individual to help preserve their considered preferences, it is ethical for that individual to interfere to prevent relapse.Footnote 72
Ethicist Arthur Caplan agrees that addiction produces a compulsion that deprives people of the “full capacity” to exercise autonomy.Footnote 73 They may be able to understand relevant treatment information, he concedes, but their lack of control leaves them unable to choose in ways that reflect their values and preferences. Caplan argues that in the context of opioid use disorder, this lack of control can justify imposing a time-limited period of naltrexone treatment to determine whether it restores the capacity to exercise autonomy.Footnote 74
Other scholars, however, question the notion that opioid addiction produces ongoing incapacity to exercise autonomy. One group of critics points to several flaws in Caplan's proposal for coercive naltrexone use. An addicted person who is “intoxicated or experiencing withdrawal symptoms” may be temporarily incapable, they say, but this can at most justify only a short-term compelled intervention like treatment to reverse overdose.Footnote 75 Such treatment is warranted because it promotes the individual's best interests. In contrast, they contend, coercive use of a six-month naltrexone implant would constitute an excessive limitation on autonomy.Footnote 76 And because the implant hasn't been proven safe and effective, Caplan cannot even cite the user's best interests to justify coercive treatment.Footnote 77
Scholars also challenge the idea that precommitment is the product of the person's genuine preferences, preferences that persist despite the person's later conflicting wishes. Anthropologist Kristen Bell observes that a binding agreement to future compelled treatment relies on the conception of “an ‘authentic self’ jeopardized by a usurping alien force.”Footnote 78 This conception merits deeper examination, she suggests, for it is not the only way to understand addiction.Footnote 79
Another challenge comes from philosopher Dan Brock, who believes that identifying which “self” is the substance user's “true self” is a more complex task than precommitment advocates have recognized.Footnote 80 In cases involving repetitive behavior like substance addiction, he suggests, “two selves alternate over time.”Footnote 81 And each self might resort to precommitment to bind the other self. Brock describes how this could work for people with drinking and gambling problems: “we can perfectly well imagine the self who is in the throes of drink or gambling seeking a precommitment strategy to prevent his sober or nongambling self from making it more difficult or impossible for him to drink or gamble.”Footnote 82 Brock contends that precommitment demands an explanation of why the choices of one self should prevail over the other, and that explanation should clearly identify a defect in the other self's reasoning.Footnote 83
According to Andreou and Caplan, that defect lies in the addicted person's cravings, which deprive the person of the capacity to exercise autonomy.Footnote 84 But there is no agreed-upon test to determine when cravings substantially diminish a drug user's decision-making capacity.Footnote 85 The absence of such a test presents a serious challenge to writers like Andreou and Caplan, for their defense of precommitment agreements assumes that evaluators can reliably differentiate the capacity of the self that is authorizing future unwanted treatment from the capacity of the self that is refusing such treatment.
2. Precommitment in General Mental Health Treatment
a. Ethical Arguments For and Against Precommitment
Writers endorsing precommitment in mental health treatment focus on psychiatric conditions like bipolar disorder that produce periodic episodes of self-destructive behavior.Footnote 86 Much of the analysis is also relevant to addiction. Some supporters think that enforcement of precommitment agreements can be justified for any individual who previously agreed to compulsory treatment. Others defend enforcement only when individuals have lost decision-making capacity. As in the addiction context, however, defining and assessing incapacity can be complicated.
Scholars defending precommitment for mental illness offer different justifications for honoring a person's advance treatment choices. Some follow Andreou in arguing that the stable and well-considered preferences expressed in a precommitment agreement continue to exist during illness episodes. For example, Julian Savulescu and Donna Dickenson believe that the preferences in mental health treatment directives represent enduring, “dispositional” preferences.Footnote 87 Momentary departures from those preferences should not, they argue, take priority over the dispositional preferences expressed in a treatment directive.Footnote 88 John Davis presents a related argument, contending that enforcing precommitment agreements can help to ensure that the “circumstances of the agent's life are consistent with his or her concurrent wishes over the longest period of time.”Footnote 89 For Ryan Spellecy, it is the planning process that elevates one set of preferences over another. Spellecy portrays precommitment agreements as the product of a deliberative planning process governed by a person's stable intentions.Footnote 90 According to Spellecy, such agreements carry greater moral weight than any immediate desires that conflict with the person's precommitment choices.Footnote 91
These writers assume that observers can accurately distinguish between a person's legitimate and illegitimate choices. They support upholding precommitment agreements even in the face of a legally competent individual's conflicting choices. According to existing law, however, individuals who remain capable of independent medical decision making remain free to alter their previous treatment choices.Footnote 92 Moreover, as John Davis observes, “it is not unheard of for people to impulsively abandon carefully-considered plans.”Footnote 93 As in the addiction context, precommitment supporters must show why the law should give priority to the competent person's advance choices. They must also explain how observers could detect when a legally competent person's desire to revoke a precommitment agreement stems from suspect, rather than genuinely autonomous, preferences.Footnote 94
In light of these problems, some precommitment supporters would limit enforcement to cases in which the individual has lost decision-making capacity.Footnote 95 On this model, surrogate decision makers acting on behalf of individuals whose mental disorder impairs their ability to understand and appreciate treatment information could turn to a precommitment agreement to guide medical decision making. This approach is easier to reconcile with existing law, as long as the usual legal standards for capacity assessment are applied.Footnote 96 Certain precommitment supporters argue for a different capacity standard in precommitment situations, however, proposing that a person's refusal of previously chosen treatment is itself an indication of the person's incapacity.Footnote 97 This would be a novel capacity standard, unrecognized under current law. Such an approach would face obstacles similar to those who say precommitment should be sufficient to override the conflicting wishes of a legally competent individual.Footnote 98
b. Therapeutic Arguments For and Against Precommitment
Besides arguing that precommitment agreements embody the most important preferences of their makers, supporters cite the therapeutic benefits that can come from creating such agreements.Footnote 99 Planning for future treatment “creates the opportunity for an important conversation and education about the future among the client, his or her doctors, caregivers, and family members.”Footnote 100 Furthermore, the very process of making an agreement can increase the person's motivation to follow the precommitment plan, reducing the likelihood of later resistance to that plan.Footnote 101 Making a directive can also enhance a person's feeling of personal responsibility and control in coping with a psychiatric problem.Footnote 102 In these ways, supporters say, precommitment promotes the shared decision making that should govern medical choices.Footnote 103
Not everyone presents such a positive picture, however. There will always be some people who resist the treatment they previously agreed to, and these individuals will experience the now-unwanted treatment as coercive.Footnote 104 Moreover, “[b]eing responsive to the patient during a crisis requires that refusals are taken seriously.”Footnote 105 Efforts to persuade patients to follow their previous choices may be acceptable, but coercion damages trust and the odds of long-term treatment success.Footnote 106 In light of these concerns, clinicians and surrogate decision makers should think seriously about the potential negative impact of imposing a medical intervention on any refusing patient. In such circumstances, a better outcome could come from seeking a resolution the patient can accept, rather than imposing a now-unwanted intervention on that patient.
III. PRECOMMITMENT AND NALTREXONE IMPLANTS
At this point, naltrexone implants are investigational devices requiring further evaluation to determine their risks and potential benefits. As long as they remain under study, their use will be governed by the federal rules protecting human subjects. The rules require researchers to permit subjects to withdraw from studies at any time. In implant research, the right to withdraw would include the right of a person with decision-making capacity to have the implant removed before the study ends.Footnote 107 In theory, a legally authorized representative would have the power to block withdrawal by an objecting study subject who has lost decision-making capacity. However, the risks and unproven nature of the implants, together with the absence of subject assent to ongoing study participation, make this an ethically questionable outcome. Thus, it is unlikely that binding agreements will become an issue while implants remain in the research phase.
If studies eventually show that implants can safely and effectively reduce relapse rates, the FDA could approve the devices for clinical use. However, the legal obstacles and ethical concerns I have described are likely to undermine efforts to incorporate binding precommitment agreements into implant use.
Proposals to allow clinicians to deny legally competent opioid users' implant removal requests would be highly controversial, likely to encounter strong opposition. Certainly, there would be challenges to such a serious infringement of patient autonomy. Opponents would also challenge claims that denying removal requests would promote the best interests of recipients deemed incapable of making the removal decision. Research in Russia and Australia documents the harm that could come from denying removal requests, including infection caused by attempted self-removal and overdose from opioid and non-opioid drugs.Footnote 108 To prevent such harm, denials of removal requests would have to be accompanied by confinement or some form of close monitoring of the protesting individual. Risks and complexities like these have reportedly made enforcement of psychiatric advance directives a relatively rare occurrence.Footnote 109 Efforts to enforce precommitment to long-term naltrexone use are likely to suffer a similar fate.
At the same time, the ethical debate over precommitment offers guidance to policymakers, clinicians, and individuals considering naltrexone implants. Although precommitment enforcement would be problematic, features of the precommitment process could be valuable in decision making about implants. Advance planning could have therapeutic benefits similar to those seen in the mental health context, possibly increasing recipients' feelings of control and investment in the treatment plan, as well as reducing the chance that they will change their minds about the device.
The precommitment debate highlights the need for researchers and clinicians to promote genuine informed consent to treatment with naltrexone implants. This includes preparing people for the difficulties they could face after the device is implanted. Before deciding on implantation, prospective recipients should not only understand and appreciate the burdens associated with long-term naltrexone treatment, they should also confront the possibility that they will want the implant removed once they experience those burdens.Footnote 110 Clinicians and prospective recipients should discuss what should happen if this occurs, creating a plan for responding to the recipient's objections to continued naltrexone treatment. The plan should include ongoing clinical and social support for implant recipients, which experts and opioid users say is crucial to maintaining the motivation to continue treatment.Footnote 111
If a recipient does request early implant removal, clinicians should discuss the previously agreed-upon plan and try to persuade the person to adhere to it. They should also discuss the reasons for the recipient's change of mind, exploring alternatives to removal that might help the recipient deal with the distress and other problems underlying the removal request. If these efforts are unsuccessful, clinicians should remove the implant and encourage the individual to begin another type of treatment for opioid use disorder. Methadone and buprenorphine are safe and effective alternative therapies that would be reasonable options for people who find naltrexone treatment too difficult.Footnote 112
Naltrexone implants could be a welcome addition to the treatment options available to people seeking medication-assisted therapy for opioid use disorder. Implants could make it easier for people to maintain their commitment to long-term sobriety. As researchers and clinicians point out, people choosing naltrexone are a relatively motivated group, able to complete full detoxification and willing to try a particularly challenging form of treatment.Footnote 113 Researchers and clinicians should build on this foundation, creating an alliance with implant recipients. Imposed treatment, even with advance consent, is unlikely to contribute to the long-term success of naltrexone implants.
I am grateful to Travis Rieder and an anonymous reviewer for helpful comments on an earlier draft.
